PL2238110T3 - Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II - Google Patents
Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny IIInfo
- Publication number
- PL2238110T3 PL2238110T3 PL09721603T PL09721603T PL2238110T3 PL 2238110 T3 PL2238110 T3 PL 2238110T3 PL 09721603 T PL09721603 T PL 09721603T PL 09721603 T PL09721603 T PL 09721603T PL 2238110 T3 PL2238110 T3 PL 2238110T3
- Authority
- PL
- Poland
- Prior art keywords
- urotensine
- bisaryl
- antagonists
- receptors
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0800651A FR2927330B1 (fr) | 2008-02-07 | 2008-02-07 | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
PCT/FR2009/000128 WO2009115665A1 (fr) | 2008-02-07 | 2009-02-05 | Dérivés de 5.6-bisaryl-2-pyr1dine-carboxamide, leur préparatio leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii |
EP09721603A EP2238110B1 (fr) | 2008-02-07 | 2009-02-05 | Dérivés de 5.6-bisaryl-2-pyr1dine-carboxamide, leur préparatio leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2238110T3 true PL2238110T3 (pl) | 2012-03-30 |
Family
ID=39434382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09721603T PL2238110T3 (pl) | 2008-02-07 | 2009-02-05 | Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II |
Country Status (22)
Country | Link |
---|---|
US (2) | US8466292B2 (fr) |
EP (1) | EP2238110B1 (fr) |
JP (1) | JP2011511046A (fr) |
KR (1) | KR20100116183A (fr) |
CN (1) | CN101981008B (fr) |
AR (1) | AR070573A1 (fr) |
AT (1) | ATE530527T1 (fr) |
AU (1) | AU2009227091B2 (fr) |
BR (1) | BRPI0907719A2 (fr) |
CA (1) | CA2715096A1 (fr) |
CY (1) | CY1112670T1 (fr) |
DK (1) | DK2238110T3 (fr) |
ES (1) | ES2375339T3 (fr) |
FR (1) | FR2927330B1 (fr) |
HR (1) | HRP20120069T1 (fr) |
IL (1) | IL207356A0 (fr) |
MX (1) | MX2010008713A (fr) |
PL (1) | PL2238110T3 (fr) |
PT (1) | PT2238110E (fr) |
RU (1) | RU2497808C2 (fr) |
SI (1) | SI2238110T1 (fr) |
WO (1) | WO2009115665A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2013326867B2 (en) | 2012-10-05 | 2018-03-08 | Rigel Pharmaceuticals, Inc. | GDF-8 inhibitors |
PT3087071T (pt) | 2013-12-24 | 2018-11-29 | Bristol Myers Squibb Co | Compostos tricíclicos como agentes anticancro |
EP4275705A3 (fr) | 2015-02-27 | 2024-01-17 | Calcimedica, Inc. | Traitement de la pancréatite |
US10683290B2 (en) | 2015-05-11 | 2020-06-16 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
KR20180034548A (ko) | 2015-07-28 | 2018-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | Tgf 베타 수용체 길항제 |
WO2017027400A1 (fr) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Utilisation d'inhibiteurs du canal crac pour le traitement d'un accident vasculaire cérébral et d'une lésion cérébrale traumatique |
EP3341372A1 (fr) | 2015-08-25 | 2018-07-04 | Bristol-Myers Squibb Company | Antagonistes du récepteur tgf bêta |
SG10201913538VA (en) | 2015-11-23 | 2020-02-27 | Five Prime Therapeutics Inc | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
SG11201806861SA (en) | 2016-03-04 | 2018-09-27 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0104332D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
EP1610753A4 (fr) * | 2003-02-20 | 2007-07-04 | Encysive Pharmaceuticals Inc | Antagonistes du recepteur de l'urotensine-ii de la phenylenediamine et antagonistes du ccr-9 |
WO2004078114A2 (fr) * | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline et naphtalene, antagonistes du recepteur de l'urotensine ii |
FR2856684B1 (fr) * | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
FR2904827B1 (fr) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
-
2008
- 2008-02-07 FR FR0800651A patent/FR2927330B1/fr not_active Expired - Fee Related
-
2009
- 2009-02-05 PT PT09721603T patent/PT2238110E/pt unknown
- 2009-02-05 CA CA2715096A patent/CA2715096A1/fr not_active Abandoned
- 2009-02-05 DK DK09721603.0T patent/DK2238110T3/da active
- 2009-02-05 AR ARP090100392A patent/AR070573A1/es not_active Application Discontinuation
- 2009-02-05 WO PCT/FR2009/000128 patent/WO2009115665A1/fr active Application Filing
- 2009-02-05 AT AT09721603T patent/ATE530527T1/de active
- 2009-02-05 CN CN2009801112181A patent/CN101981008B/zh not_active Expired - Fee Related
- 2009-02-05 SI SI200930139T patent/SI2238110T1/sl unknown
- 2009-02-05 EP EP09721603A patent/EP2238110B1/fr active Active
- 2009-02-05 BR BRPI0907719-7A patent/BRPI0907719A2/pt not_active IP Right Cessation
- 2009-02-05 KR KR1020107017495A patent/KR20100116183A/ko not_active Application Discontinuation
- 2009-02-05 PL PL09721603T patent/PL2238110T3/pl unknown
- 2009-02-05 RU RU2010137115/04A patent/RU2497808C2/ru not_active IP Right Cessation
- 2009-02-05 JP JP2010545523A patent/JP2011511046A/ja active Pending
- 2009-02-05 ES ES09721603T patent/ES2375339T3/es active Active
- 2009-02-05 AU AU2009227091A patent/AU2009227091B2/en not_active Ceased
- 2009-02-05 MX MX2010008713A patent/MX2010008713A/es active IP Right Grant
-
2010
- 2010-08-02 IL IL207356A patent/IL207356A0/en unknown
- 2010-08-06 US US12/851,941 patent/US8466292B2/en not_active Expired - Fee Related
-
2012
- 2012-01-23 HR HR20120069T patent/HRP20120069T1/hr unknown
- 2012-01-25 CY CY20121100089T patent/CY1112670T1/el unknown
-
2013
- 2013-05-15 US US13/894,872 patent/US8653276B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101981008A (zh) | 2011-02-23 |
JP2011511046A (ja) | 2011-04-07 |
EP2238110A1 (fr) | 2010-10-13 |
US8653276B2 (en) | 2014-02-18 |
PT2238110E (pt) | 2012-01-02 |
AR070573A1 (es) | 2010-04-21 |
CA2715096A1 (fr) | 2009-09-24 |
WO2009115665A1 (fr) | 2009-09-24 |
BRPI0907719A2 (pt) | 2015-07-14 |
FR2927330A1 (fr) | 2009-08-14 |
RU2497808C2 (ru) | 2013-11-10 |
EP2238110B1 (fr) | 2011-10-26 |
RU2010137115A (ru) | 2012-03-20 |
ES2375339T3 (es) | 2012-02-29 |
AU2009227091B2 (en) | 2013-05-23 |
KR20100116183A (ko) | 2010-10-29 |
US20110009426A1 (en) | 2011-01-13 |
HRP20120069T1 (hr) | 2012-02-29 |
SI2238110T1 (sl) | 2012-02-29 |
MX2010008713A (es) | 2010-09-09 |
FR2927330B1 (fr) | 2010-02-19 |
CY1112670T1 (el) | 2016-02-10 |
ATE530527T1 (de) | 2011-11-15 |
DK2238110T3 (da) | 2012-02-20 |
IL207356A0 (en) | 2010-12-30 |
US8466292B2 (en) | 2013-06-18 |
US20130252974A1 (en) | 2013-09-26 |
CN101981008B (zh) | 2013-07-31 |
AU2009227091A1 (en) | 2009-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2238110T1 (sl) | Derivati 5,6-bisaril-2-piridin-karboksamida, njihova priprava in njihova terapevtska uporaba kot antagonisti receptorjev urotenzina II | |
EP2121658A4 (fr) | Dérivés pipérazinyl-propyl-pyrazole servant d'antagonistes aux récepteurs dopaminergiques d4, et compositions pharmaceutiques les contenant | |
IL206765A0 (en) | 4,5-dihydro-oxazol-2-yl-amine derivatives | |
IL193467A0 (en) | Substituted indazole derivatives, their manufacture and use as pharmaceutical agents | |
IL206395A (en) | N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them | |
IL196671A0 (en) | Substituted imidazolone derivatives, preparation and uses | |
IL201973A0 (en) | 3,3-spiroindolinone derivatives | |
EP2222659A4 (fr) | Indoles, dérivés et leurs analogues et leurs utilisations | |
EP2157093A4 (fr) | Dérivés pyrrolo-azotés hétérocycliques, leur préparation et leur utilisation pharmaceutique | |
DK2094690T3 (da) | 2-aza-bicyclo[3.1.0]hexanderivater som orexinreceptorantagonister | |
IL206808A (en) | Indolyl-pyridone history, their pharmaceutical preparations and their uses | |
ZA200800320B (en) | Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists | |
HK1159108A1 (en) | Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof | |
ZA201001797B (en) | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | |
PL2401263T3 (pl) | Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu | |
ZA201008657B (en) | 4,5-dihydro-oxazol-2-yl derivatives | |
IL195972A0 (en) | Cinnamoyl-piperazine derivatives and their use as par-i antagonists | |
IL213452A0 (en) | Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | |
EP2354136A4 (fr) | Nouveaux ligands de récepteurs d3 de la dopamine, leurs procédés de préparation et leurs applications | |
EP2208732A4 (fr) | Vancomycine déshydroxylée, sa préparation, composition pharmaceutique et son utilisation | |
IL207629A0 (en) | Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof | |
IL193384A0 (en) | Substituted prolinamides, their preparation and their use as pharmaceuticals | |
EP2264031A4 (fr) | Nouveau dérivé de benzoxazine benzimidazole, composition pharmaceutique le comprenant et application s'y rapportant | |
EP2119720A4 (fr) | Nouveaux dérivées de la vinblastine, leur préparation, et compositions pharmaceutiques les comprenant. | |
IL212170A (en) | Mineral corticoid receptor antagonists, their atrophy isomers, their medicinal preparations and their use |